Results 241 to 250 of about 142,425 (303)

GRKs and arrestins: Nomenclature and functions in GPCR‐dependent and ‐independent signalling

open access: yesBritish Journal of Pharmacology, EarlyView.
G protein‐coupled receptor (GPCR) kinases (GRKs) and arrestins play a critical role in the regulation of GPCR signalling. Historic names of mammalian GRKs were replaced by systematic ones in the 1990s; however, both kinds of names are currently in use for mammalian arrestins.
Vsevolod V. Gurevich
wiley   +1 more source

Docetaxel‐Induced Immune Activation Shows Antitumor Synergy With the Tumor‐Targeted CD40 Agonist KK2269

open access: yesCancer Science, EarlyView.
CD40 agonists have demonstrated proof‐of‐concept for converting an immunologically cold tumor into a hot tumor in preclinical studies; however, clinically, they have shown limited antitumor efficacy as monotherapy. We tested a tumor‐targeted CD40 agonist, KK2269 (a bispecific antibody that binds to CD40 and EpCAM), in combination with various ...
Yuta Tezuka   +5 more
wiley   +1 more source

Telomere-to-telomere genome assembly of the Dipteran Bactrocera dorsalis from a single individual. [PDF]

open access: yesNat Commun
Liu W   +9 more
europepmc   +1 more source

Downregulation of MLL1 Promotes Intestinal Epithelial Barrier Repair Through Gata4/Bmp4 Activation to Ameliorate Crohn's Disease‐Like Colitis in Mice

open access: yesCell Proliferation, EarlyView.
This study elucidates the pivotal regulatory role and mechanism of MLL1 in inflammatory bowel disease. Experimental data demonstrated elevated MLL1 expression levels in TNBS‐induced murine colitis models, with pharmacological inhibition of MLL1 significantly promoting recovery from CD‐like colitis by accelerating intestinal barrier restoration ...
Xue Song   +12 more
wiley   +1 more source

Synthetic rewriting technologies in mammalian cells. [PDF]

open access: yesNat Commun
Wang Y, Cui Y, Zhao GR, Wu Y, Yuan YJ.
europepmc   +1 more source

Regional Standardization of CLL Management: Results of a Delphi Consensus Process

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT The therapeutic landscape of chronic lymphocytic leukemia (CLL) has been profoundly transformed by the introduction of Bruton tyrosine kinase and BCL‐2 inhibitors. Despite improved survival outcomes, treatment selection remains complex, particularly in older patients with comorbidities, frailty, and increased infectious vulnerability.
Enrica Antonia Martino   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy